Sign in
Taking people in United KingdomPhase 1

Tests donor-derived T cells engineered to target CD19 in advanced blood cancers

Tests KCAT19 T cells in adults with relapsed or hard-to-treat CD19-positive blood cancers.

Key facts

Who runs it
University College, London
Where
London, United KingdomSee the site
Registry title
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies
Status
Recruiting
Phase
Phase 1
People taking part
12 people, planned
Started
6 Feb 2023
Expected to end
Feb 2040
Type of study
Interventional
Treatments tested
  • KCAT19 T cells
Record updated
11 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 16-65 whose B cell blood cancer has come back or has not responded after at least 2 earlier treatments, and whose cancer cells carry CD19.

Age
16-65 years
Sex
All sexes can join.
Disease stage
Relapsed or refractory B cell cancer after at least 2 prior lines of therapy: B-ALL, large B cell lymphoma (DLBCL or PMBCL), mantle cell lymphoma, or indolent B-NHL (follicular, marginal zone or other low-grade lymphoma).
Earlier treatment
At least 2 earlier lines of therapy. For large B cell lymphoma these must include Rituximab, an anthracycline and autologous CD19 CAR. For mantle cell lymphoma: Rituximab, a Bruton's tyrosine kinase inhibitor and autologous CD19 CAR. For indolent B-NHL: anti-CD20 therapy and chemotherapy with anthracycline or bendamustine. CD19 CAR is not needed if it cannot be made.
Biomarker or test result
CD19-positive disease.

Main reasons for not taking part

  • CD19-negative disease or active cancer in the central nervous system
  • Chronic lymphocytic leukaemia, small lymphocytic lymphoma or Burkitt lymphoma
  • Active hepatitis B, hepatitis C or HIV infection
  • Pregnant or breast feeding
  • Can reasonably get autologous CD19 CAR treatment as standard care or in another trial

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Age 16-65 years
  • Relapsed or refractory B cell malignancy following at least 2 prior lines of therapy:; B-ALL: relapsed or refractory B-ALL following standard therapy, requiring salvage, in whom alternative therapies are deemed inappropriate by their treating physician Or LBCL: relapsed/refractory DLBCL (incl. transformed FL but not Richter's transformation) or PMBCL following ≥2 prior lines of therapy which must include Rituximab, anthracycline and autologous CD19 CAR, (unless CD19 CAR cannot be manufactured) Or MCL: relapsed/ refractory disease following ≥2 lines of therapy which must include Rituximab, Bruton's tyrosine kinase inhibitor and autologous CD19CAR therapy (unless CD19 CAR cannot be manufactured) Or Indolent B-NHL (either Follicular Lymphoma, Marginal Zone Lymphoma or other low-grade lymphoma) which is relapsed / refractory following ≥2 prior lines of therapy which must include anti-CD20 therapy and chemotherapy with anthracycline or bendamustine
  • CD19+ disease
  • Agreement to have a pregnancy test, use adequate contraception (if applicable)
  • Written informed consent

Who cannot take part

  • Stem Cell Transplant patients only: active significant acute GvHD (overall Grade ≥ II, Modified Glucksberg criteria) or moderate/severe chronic GvHD (NIH consensus criteria) requiring immunosuppressive therapy and/or systemic steroids
  • Patients receiving corticosteroids at a dose of >5 mg prednisolone per day (or equivalent) that cannot be discontinued
  • CD19 negative disease
  • Active CNS involvement of disease
  • Active hepatitis B, C or HIV infection
  • Bilirubin >2 x upper limit of normal
  • GFR <30ml/min
  • Known allergy to albumin or DMSO
  • Cardiac dysrhythmias (excluding well-controlled AF or other supraventricular tachycardia) or significant cardiac disease and left ventricular ejection fraction <40%
  • Diagnosis of chronic lymphocytic leukaemia/ small lymphocytic lymphoma or Burkitt lymphoma
  • Oxygen saturation ≤ 90% on air
  • Women who are pregnant or breast feeding
  • Karnofsky score <60%
  • Life expectancy <3 months
  • Patients who can reasonably access autologous CD19 CAR treatment as part of standard of care or a clinical trial*; These patients will be initially considered for autologous treatment in preference to enrolling on KCAT19

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 16 and 65 years old?

Where in United Kingdom

  • University College London HospitalLondon, United KingdomContact: David GearTaking people

About the trial

What the trial wants to find out

KCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.

The group in the trial

  • Single Arm TrialTreatment being tested

    Treatment with Lymphodepletion followed by a dose of KCAT19 T cells.

    Treatment: KCAT19 T cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies
Plain-language title
Tests donor-derived T cells engineered to target CD19 in advanced blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05391490, who can take part
Record updated
11 August 2026